Herbalife Ltd. (HLF) stock

HLFNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 10/3053% below fair value

$13.05+0.12 (+0.93%)

Close on Oct 30, 2026Market cap $1.37BP/E 8.4Yield –

Earnings

Herbalife's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 4, 2026

Q3 FY2026 · estimated, during market hours

Revenue, Q2 FY2026

$1.30B

0.0% on a year earlier

adjusted diluted EPS, Q2 FY2026

$0.51

$0.59 a year earlier

Latest guidance

Raised

Aug 5, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Herbalife's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 4, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 5, 2026during market hours	$1.30B	0.0%	-$0.25	$0.51	Release
Q1 FY2026ended Mar 31, 2026	Apr 14, 2026before the open	–	–	–	–	Release
Q4 FY2025ended Dec 31, 2025	Feb 18, 2026during market hours	$1.30B	+8.3%	$0.81	$0.45	Release
Q3 FY2025ended Sep 30, 2025	Nov 5, 2025during market hours	$1.30B	+8.3%	$0.42	$0.50	Release
Q2 FY2025ended Jun 30, 2025	Aug 6, 2025during market hours	$1.30B	0.0%	$0.48	$0.59	Release
Q1 FY2025ended Mar 31, 2025	Apr 30, 2025during market hours	$1.20B	-7.7%	$0.49	$0.59	Release
Q4 FY2024ended Dec 31, 2024	Feb 19, 2025during market hours	$1.20B	0.0%	$1.74	$0.36	Release
Q3 FY2024ended Sep 30, 2024	Oct 30, 2024during market hours	$1.20B	-7.7%	$0.46	$0.57	Release
Q2 FY2024ended Jun 30, 2024	Jul 31, 2024during market hours	$1.30B	0.0%	$0.05	$0.54	Release
Q1 FY2024ended Mar 31, 2024	May 1, 2024during market hours	$1.30B	0.0%	$0.24	$0.49	Release
Q4 FY2023ended Dec 31, 2023	Feb 14, 2024during market hours	$1.20B	0.0%	$0.10	$0.28	Release
Q3 FY2023ended Sep 30, 2023	Nov 1, 2023during market hours	$1.30B	0.0%	$0.43	$0.65	Release
Q2 FY2023ended Jun 30, 2023	Aug 2, 2023during market hours	$1.30B	-7.1%	$0.60	$0.74	Release
Q1 FY2023ended Mar 31, 2023	May 2, 2023during market hours	$1.30B	0.0%	$0.29	$0.54	Release
Q4 FY2022ended Dec 31, 2022	Feb 14, 2023during market hours	$1.20B	-7.7%	$0.55	$0.53	Release
Q3 FY2022ended Sep 30, 2022	Oct 31, 2022during market hours	$1.30B	-7.1%	$0.83	$0.91	Release
Q2 FY2022ended Jun 30, 2022	Aug 2, 2022during market hours	$1.40B	–	$0.88	$0.96	Release
Q1 FY2022ended Mar 31, 2022	May 3, 2022during market hours	$1.30B	–	$0.96	$0.99	Release
Q4 FY2021ended Dec 31, 2021	Feb 23, 2022during market hours	$1.30B	–	$0.37	$0.57	Release
Q3 FY2021ended Sep 30, 2021	Nov 2, 2021during market hours	$1.40B	–	$1.09	$1.21	Release
Q2 FY2021ended Jun 30, 2021	Aug 3, 2021during market hours	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 4, 2021during market hours	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 17, 2021during market hours	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Nov 5, 2020during market hours	–	–	–	–	Filing
Q2 FY2020ended Jun 30, 2020	Jul 13, 2020before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Herbalife's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Net SalesGAAP	Q3 FY2026	+0.5% – +4.5%	–	New	Aug 5, 2026
Net Sales - Constant Currencynon-GAAP	Q3 FY2026	+1.5% – +5.5%	–	New	Aug 5, 2026
Net SalesGAAP	FY2026	+2.5% – +5.5%	+1% – +6%	Narrowed	Aug 5, 2026
Net Sales - Constant Currencynon-GAAP	FY2026	+2.5% – +5.5%	0% – +5%	Raised	Aug 5, 2026
Adjusted effective tax ratenon-GAAP	FY2026	35%	30%	Raised	Aug 5, 2026
Capitalized SaaS implementation costs	FY2026	$35.00M – $55.00M	$40.00M – $60.00M	Lowered	Aug 5, 2026
Depreciation and amortization, and amortization of SaaS implementation costs	FY2026	$140.00M – $150.00M	$140.00M – $150.00M	Raised	Aug 5, 2026

Guidance vs results

The last range Herbalife gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Revenue growth	-0.3% – +0.7%	+2%Σ4Q	Above range
Q4 FY2025	Revenue growth	+1.5% – +5.5%	+8.33%	Above range
Q3 FY2025	Revenue growth	+0.5% – +4.5%	+8.33%	Above range
Q3 FY2024	Revenue growth	-4.5% – 0%	-7.69%	Below range
Q2 FY2024	Revenue growth	0% – +3%	0%	Within range
Q3 FY2022	Adjusted Diluted EPS	$0.70 – $0.95	$0.91	Within range
Q3 FY2022	Revenue growth	-9% – -3%	-7.14%	Within range
Q2 FY2022	Adjusted Diluted EPS	$0.60 – $0.80	$0.96	Above range
Q1 FY2022	Adjusted Diluted EPS (a) (b) (c)	$0.80 – $1.00	$0.99	Within range

Guidance history

Every forecast Herbalife put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 5, 2026	Adjusted effective tax rate	FY2026	35%	Raised
Aug 5, 2026	Capitalized SaaS implementation costs	FY2026	$35.00M – $55.00M	Lowered
Aug 5, 2026	Depreciation and amortization, and amortization of SaaS implementation costs	FY2026	$140.00M – $150.00M	Raised
Aug 5, 2026	Net Sales	FY2026	+2.5% – +5.5%	Narrowed
Aug 5, 2026	Net Sales - Constant Currency	FY2026	+2.5% – +5.5%	Raised
Aug 5, 2026	Net Sales	Q3 FY2026	+0.5% – +4.5%	New
Aug 5, 2026	Net Sales - Constant Currency	Q3 FY2026	+1.5% – +5.5%	New
Feb 18, 2026	Adjusted effective tax rate	FY2026	30%	New
Feb 18, 2026	Capitalized SaaS implementation costs	FY2026	$40.00M – $60.00M	New
Feb 18, 2026	Depreciation and amortization, and amortization of SaaS implementation costs	FY2026	$140.00M – $150.00M	Raised
Feb 18, 2026	Net Sales	FY2026	+1% – +6%	New
Feb 18, 2026	Net Sales	FY2026	0% – +5%	New
Feb 18, 2026	Net Sales	Q1 FY2026	+3% – +7%	New
Feb 18, 2026	Net Sales	Q1 FY2026	+0.5% – +4.5%	New
Nov 5, 2025	Adjusted EBITDA	FY2025	$645.00M – $655.00M	New
Nov 5, 2025	Adjusted EBITDA Constant Currency	FY2025	$700.00M – $710.00M	Raised
Nov 5, 2025	Adjusted EBITDA	Q4 FY2025	$144.00M – $154.00M	New
Nov 5, 2025	Adjusted EBITDA Constant Currency	Q4 FY2025	$154.00M – $164.00M	Raised
Nov 5, 2025	Net Sales	FY2025	-0.3% – +0.7%	New
Nov 5, 2025	Net Sales Constant Currency	FY2025	+1.2% – +2.2%	New
Nov 5, 2025	Net Sales	Q4 FY2025	+1.5% – +5.5%	New
Nov 5, 2025	Net Sales Constant Currency	Q4 FY2025	+0.5% – +4.5%	New
Aug 6, 2025	CapEx	Q3 FY2025	$20.00M – $30.00M	New
Aug 6, 2025	CapEx	FY2025	$75.00M – $95.00M	New
Aug 6, 2025	Adjusted EBITDA	Q3 FY2025	$150.00M – $160.00M	New
Aug 6, 2025	Adjusted EBITDA	FY2025	$640.00M – $660.00M	New
Aug 6, 2025	Net Sales	Q3 FY2025	+0.5% – +4.5%	New
Aug 6, 2025	Net Sales	Q3 FY2025	+0.5% – +4.5%	New
Aug 6, 2025	Net Sales	FY2025	-1% – +3%	New
Aug 6, 2025	Net Sales	FY2025	0% – +4%	New
Feb 19, 2025	total capitalized SaaS implementation costs	FY2025	$25.00M – $30.00M	New
Jul 31, 2024	Capital Expenditures	Q3 FY2024	$35.00M – $45.00M	New
Jul 31, 2024	Capital Expenditures	FY2024	$120.00M – $150.00M	Reaffirmed
Jul 31, 2024	Adjusted EBITDA	Q3 FY2024	$125.00M – $155.00M	New
Jul 31, 2024	Adjusted EBITDA	FY2024	$560.00M – $600.00M	Raised
Jul 31, 2024	Net Sales	Q3 FY2024	-4.5% – 0%	New
Jul 31, 2024	Net Sales	FY2024	-3.5% – +1.5%	Lowered
May 1, 2024	Capital Expenditures	Q2 FY2024	$30.00M – $40.00M	New
May 1, 2024	Capital Expenditures	FY2024	$120.00M – $150.00M	New
May 1, 2024	Adjusted EBITDA	Q2 FY2024	$140.00M – $160.00M	New
May 1, 2024	Adjusted EBITDA	FY2024	$550.00M – $590.00M	New
May 1, 2024	Net Sales	Q2 FY2024	0% – +3%	New
May 1, 2024	Net Sales	FY2024	0% – +5%	New
Feb 14, 2024	total capital expenditures	FY2024	$145.00M – $195.00M	New
Nov 1, 2023	total capital expenditures	FY2023	$120.00M – $160.00M	Lowered
Aug 2, 2023	capital expenditures	FY2023	$150.00M – $200.00M	New
Aug 2, 2022	Cap Ex	FY2022	$175.00M – $225.00M	Reaffirmed
Aug 2, 2022	Adjusted EBITDA	Q3 FY2022	$160.00M – $180.00M	New
Aug 2, 2022	adjusted 2 EBITDA	FY2022	$680.00M – $740.00M	Reaffirmed
Aug 2, 2022	Adjusted Diluted EPS	Q3 FY2022	$0.70 – $0.95	New
Aug 2, 2022	adjusted 2 EPS	FY2022	$3.25 – $3.75	Lowered
Aug 2, 2022	Volume Point Growth (Decline) vs 2021	Q3 FY2022	-14% – -8%	New
Aug 2, 2022	Volume Point Growth (Decline) vs 2021	FY2022	-12.5% – -6.5%	Reaffirmed
Aug 2, 2022	Net Sales Growth (Decline) vs 2021	Q3 FY2022	-9% – -3%	New
Aug 2, 2022	net sales	FY2022	-10% – -4%	Reaffirmed
May 3, 2022	Cap Ex	FY2022	$175.00M – $225.00M	New
May 3, 2022	Adjusted EBITDA	Q2 FY2022	$135.00M – $155.00M	New
May 3, 2022	adjusted EBITDA guidance	FY2022	$680.00M – $740.00M	Lowered
May 3, 2022	Adjusted Diluted EPS	Q2 FY2022	$0.60 – $0.80	New
May 3, 2022	adjusted diluted EPS guidance range	FY2022	$3.50 – $4.00	Lowered
May 3, 2022	Volume Point Growth vs 2021	Q2 FY2022	-18% – -12%	New
May 3, 2022	Volume Point Growth vs 2021	FY2022	-12.5% – -6.5%	Lowered
May 3, 2022	Net Sales Growth vs 2021	Q2 FY2022	-17.5% – -11.5%	New
May 3, 2022	net sales guidance range	FY2022	-10% – -4%	New
Feb 23, 2022	Cap Ex ($ millions)	FY2022	$175.00M – $225.00M	New
Feb 23, 2022	Adjusted EBITDA ($ millions) (a) (c)	Q1 FY2022	$165.00M – $185.00M	New
Feb 23, 2022	Adjusted EBITDA ($ millions) (a) (c)	FY2022	$785.00M – $845.00M	New
Feb 23, 2022	Adjusted Diluted EPS (a) (b) (c)	Q1 FY2022	$0.80 – $1.00	New
Feb 23, 2022	Adjusted Diluted EPS (a) (b) (c)	FY2022	$4.25 – $4.75	New
Feb 23, 2022	Volume Point Growth vs 2021	Q1 FY2022	-9.5% – -3.5%	New
Feb 23, 2022	Volume Point Growth vs 2021	FY2022	-2% – +4%	New
Feb 23, 2022	Net Sales Growth vs 2021 (a)	Q1 FY2022	-10% – -4%	New
Feb 23, 2022	Net Sales Growth vs 2021 (a)	FY2022	0% – +6%	New
Nov 2, 2021	Cap Ex ($ millions)	FY2021	$145.00M – $175.00M	New
Nov 2, 2021	Adjusted EBITDA ($ millions) (a) (b) (c)	FY2021	$860.00M – $910.00M	New
Nov 2, 2021	Adjusted Diluted EPS (a) (b) (c)	FY2021	$4.55 – $4.95	New
Nov 2, 2021	Volume Point Growth vs 2020	FY2021	+1% – +5%	New
Nov 2, 2021	Net Sales Growth vs 2020 (a)	FY2021	+4.5% – +8.5%	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.